M&As this week: Grifols and CoverMyMeds

2 February 2017 (Last Updated February 2nd, 2017 18:30)

As a part of its growth strategy, Global health care company, Grifols, has acquired the Nucleic Acid Testing (NAT) donor screening unit from Hologic in a $1.85bn deal.

As a part of its growth strategy, Global health care company, Grifols, has acquired the Nucleic Acid Testing (NAT) donor screening unit from Hologic in a $1.85bn deal.

The NAT unit, which conducts research and development (R&D) and manufactures assays and instruments for transfusion and transplantation screening, was Hologic’s interest in the joint-business held by both the companies. The acquired assets also include a plant in San Diego, development rights, licenses to patents and access to product manufacturers.

The acquisition enables the Spanish company to strengthen its position in transfusion medicine through NAT technology.

"The acquisition enables the Spanish company to strengthen its position in transfusion medicine through NAT technology."

CoverMyMeds, a healthcare technology company specialising in electronic prior authorisation (ePA) solutions, will be acquired by healthcare and information technology provider McKesson Corporation, for up to $1.4bn.

CoverMyMeds’ ePA solutions automate and accelerate the prescription approval process, and help customers to avoid administrative waste and unnecessary expenses caused by prescription abandonment.

Though the two companies are working together towards their common mission to improve their health care business since 2010, the pending acquisition will enable them to enhance the value they provide to their customers across the health care spectrum.